Cancer Evaluation Articles & Analysis
37 news found
Other candidates have already been constructed and are undergoing preclinical evaluation, against HPV induced cancers or infectious diseases. The joint Institut Pasteur – Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses. ...
ByOncoVITA
” “Each year 300,000 Americans are diagnosed with breast cancer and metastatic breast cancer causes the vast majority of deaths from the disease: more than 43,000 annually. ...
In addition to the above studies, it is currently being evaluated in prostate cancer with further potential in pancreatic, ovarian and colorectal cancers. ...
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of ...
Also, the early detection of cancer is often limited by high false-positives and/or poor sensitivity to early-stage cancer. ...
Cancer Research Communications is an open access peer-reviewed journal published by the American Association for Cancer Research. The study was conducted as a collaboration between Atrium Health Levine Cancer Institute, Sanofi, and GeneCentric and evaluated real-world data from patients diagnosed with renal cell carcinoma (RCC) ...
A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography (‘OCT’) technology, which can transform patient’s treatment and care of basal cell carcinomas (BCC). It was concluded that OCT-guided diagnosis, when ...
Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory diseases, allergies, sepsis, and cancer. Cytokines play an important role in physiological and pathological processes such as immune cell differentiation and subset development, immune regulation, inflammatory response, and tumor ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. ...
The expansion cohorts include patients with renal cell carcinoma (clear cell), non-small cell lung cancer (EFGR mutant), and colorectal cancer. Enrollment continues in the phase 1/2a combination study of AFM24 with the anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) (AFM24-102) to treat patients with non-small cell lung cancer ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version ...
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine. TG4050 is currently being evaluated in two ongoing multicenter Phase I trials in patients ...
” To advance the adoption of digital pathology worldwide, 4D Path and PathPresenter have created exclusive educational content to teach current and future pathologists about how evaluation of breast cancer features prior to downstream genomic and molecular testing can potentially improve patient care. ...
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and ...
Oppenheimer's 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2021 Time: 8:00 AM ET Presentation Format: Fireside Chat About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using ...
In the study, a diverse set of 38 providers from both community-based practices and academic locations within the Cleveland Clinic health system enrolled 900 men being evaluated for prostate cancer, readily adopted IsoPSA, and utilized IsoPSA results in their patient management decisions. ...
About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and ...
The results were particularly encouraging given that patients were not preselected on the basis of predictors of immune response in prostate cancer.” KEY SCNC FINDINGS In the evaluable patient cohort (n = 15), 5 (33%) patients achieved a composite response at the planned interim analysis. ...